首页> 美国卫生研究院文献>Cancer Management and Research >Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4 CA125 CA19-9 and CEA in ovarian tumors

【2h】

Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4 CA125 CA19-9 and CEA in ovarian tumors

机译：458例卵巢肿瘤患者四种血清肿瘤标志物的临床分析：HE4CA125CA19-9和CEA联合应用对卵巢肿瘤的诊断价值

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeTo investigate the diagnostic values of human epididymis protein 4 (HE4), carbohydrate antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9), and carcinoembryonic antigen (CEA) for ovarian tumors.

机译：目的探讨人附睾蛋白4（HE4），碳水化合物抗原125（CA125），碳水化合物抗原19-9（CA19-9）和癌胚抗原（CEA）对卵巢肿瘤的诊断价值。

著录项

期刊名称 Cancer Management and Research
作者
Fawen Chen; Jing Shen; Jianwei Wang; Pengwei Cai; Yi Huang;
展开▼
作者单位

展开▼
年(卷),期 2018(10),-1
年度 2018
页码 1313–1318
总页数 6
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
human epididymis protein 4 carbohydrate antigen 125 carbohydrate antigen 19-9 carcinoembryonic antigen pelvic tumor;

机译：人附睾蛋白4;碳水化合物抗原125;碳水化合物抗原19-9;癌胚抗原;骨盆肿瘤;

相似文献

外文文献
中文文献
专利

1. Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors [J] . Fawen Chen, Jing Shen, Jianwei Wang, Cancer Management and Research . 2018,第SpecaNoaA期

机译：458例卵巢肿瘤患者四种血清肿瘤标志物的临床分析：HE4，CA125，CA19-9和CEA联合应用对卵巢肿瘤的诊断价值
2. Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors [J] . Fawen Chen, Jing Shen, Jianwei Wang, Cancer Management and Research . 2018,第1期

机译：458例卵巢肿瘤患者四种血清肿瘤标志物的临床分析：HE4，CA125，CA19-9和CEA联合应用对卵巢肿瘤的诊断价值
3. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. [J] . Jacob F, Meier M, Caduff R, Gynecologic Oncology: An International Journal . 2011,第3期

机译：在临床环境中，将HE4和CA125组合为卵巢肿瘤标记物无济于事。
4. Spectropolarimetry diagnostics of blood and punctate Douglas deepening in patients with ovarian tumors [C] . Sergey Yermolenko, Olexander Peresunko, Ion Gruia, Advanced Topics in Optoelectronics, Microelectronics, and Nanotechnologies . 2019

机译：卵巢肿瘤患者深化血液和点状Douglas的光谱诊断
5. The development of intratumoral heterogeneity in ovarian tumors: Role of cancer stem cells in disease progression. [D] . Lunsford, Elaine P. 2014

机译：卵巢肿瘤内肿瘤异质性的发展：癌症干细胞在疾病进展中的作用。
6. Does the Risk of Ovarian Malignancy Algorithm Provide Better Diagnostic Performance Than HE4 and CA125 in the Presurgical Differentiation of Adnexal Tumors in Polish Women? [O] . Nabil Abdalla, Robert Piorkowski, Michal Bachanek, 2018

机译：在波兰女性的肾上腺肿瘤的术前鉴别中卵巢恶性算法的风险是否比HE4和CA125提供更好的诊断性能？
7. Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors [O] . Fawen Chen, Jing Shen, Jianwei Wang, 2018

机译：458例卵巢肿瘤患者四种血清肿瘤标志物的临床分析：卵巢肿瘤中HE4，CA125，CA19-9和CEA联合使用的诊断价值
8. Tumor Marker CA 125: The Clinical Significance of the Serum Marker CA 125 in the Management of Patients with Ovarian Cancer [R] . van der Burg, M. E. L. 1989

机译：肿瘤标志物Ca 125：血清标志物Ca 125在卵巢癌患者管理中的临床意义

Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4 CA125 CA19-9 and CEA in ovarian tumors

摘要

著录项

相似文献

相关主题

期刊订阅